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ABSTRACT The effects of MPTP treatment (4 3 10 mg/kg, 2-h intervals) on in vivo
striatal binding of (1)-a-[3H]dihydrotetrabenazine ((1)-[3H]DTBZ) to the vesicular
monoamine transporter type 2 (VMAT2) were examined in wild type (1,1) and tottering
(tg/tg) mice of the C57BL/6J strain. The tottering mutant has been previously character-
ized as having hyperinnervation of noradrenergic terminals in the brain, with increased
concentrations of norepinephrine and increased numbers of VMAT2 binding sites. In
wild-type mice, MPTP caused a significant decrease in specific striatal (1)-[3H]DTBZ
binding in both males (-71%) and females (-57%), consistent with dopaminergic terminal
losses. In the tottering mice, the neurotoxic effects of MPTP were diminished, with
smaller losses of (1)-[3H]DTBZ binding observed both in males (-45%) and females
(-26%). These results are consistent with the hypothesis that vesicular storage (as a
result of hyperinnervation) offers neuroprotection toward MPTP toxicity, although the
confounding effects of increases in norepinephrine concentrations or changes in calcium
ion channel function (both also characteristics of the tottering mutant) cannot be ruled
out. The tottering mutant does, however, offer another animal model to examine the
biochemical features responsible for MPTP toxicity. Synapse 30:205–210, 1998.
r 1998 Wiley-Liss, Inc.
INTRODUCTION
A satisfactory explanation for the species and strain
selectivity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyri-
dine (MPTP) toxicity to dopaminergic neurons of the
brain is still lacking. Although the metabolic enzyme
monoamine oxidase B and the neuronal membrane
dopamine transporter are required for production and
intracellular localization of the neurotoxic species
1-methyl-4-phenylpyridinium (MPP1), the toxicity of
MPTP does not correlate with numbers or activities of
the enzyme or transporter (Liu and Edwards, 1997). A
good correlation has been reported between brain tis-
sue levels of MPP1 and losses of striatal dopamine in
vivo among mouse strains (Giovanni et al., 1991),
although studies within a single strain of mice found a
poor correlation between striatal MPP1 level and dopa-
mine loss (Vaglini et al., 1996). The resistance of rats to
MPTP remains difficult to explain, as rats are reported
to accumulate MPP1 to brain tissue levels higher than
mice (Giovanni et al., 1991; Nwanze et al., 1995).
Recently, a number of investigators have suggested
that differential compartmentalization of MPP1 might
offer a method of neuroprotection; such sequestration of
the toxin might be accomplished by storage in vesicles
via the actions of the vesicular monoamine transporter
type 2 (VMAT2) (Russo et al., 1994; Zuddas et al., 1994).
This vesicular transporter is specific for the monoamin-
ergic neurons in the brain and is very capable of moving
MPP1 from the cytosol into the lumen of the vesicle (Liu
and Edwards, 1997), thus removing it from potential
interactions with mitochondrial complex I sites and the
subsequent inhibition of cellular energy metabolism.
Evidence for the importance of VMAT2 in MPTP toxic-
ity comes from pharmacological and genetic studies.
Pretreatment of animals with inhibitors of the trans-
porter, such as tetrabenazine or reserpine, potentiates
the toxicity of MPTP (Reinhard et al., 1988; Russo et al.,
1994). Reductions of the numbers of VMAT2 in hetero-
zygous knockout mice (.50% loss of [3H]dihydrotetra-
benazine binding to the transporter in the striatum)
results in greater than double the toxicity of MPTP, as
measured by losses of tissue dopamine (Takahashi et
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al., 1997). Both of these experiments support a role of
VMAT2 in the dopaminergic neurotoxicity of MPTP.
These pharmacological and transgenic mouse studies
have indicated that decreased numbers or availability
of VMAT2 results in increased MPTP neurotoxicity. It
would be equally interesting to demonstrate that in-
creased vesicular storage capability results in de-
creased toxicity of MPTP. This might be done using a
pharmacological treatment which upregulates the num-
bers of VMAT2 and/or the numbers of vesicles, but we
and others have shown that the levels of VMAT2
protein cannot be regulated by administration of dopa-
minergic or cholinergic drugs, even where clear regula-
tion of other functions of the dopaminergic system (e.g.,
neuronal membrane dopamine transporters and dopa-
mine receptors) can be demonstrated (for review, see
Kilbourn et al., 1997). Use of multiple strains of mice
with different striatal concentrations of VMAT2 (if such
were to be identified) would be complicated by potential
differences in peripheral metabolism of the neurotoxin,
which may account for some or all of the unusually high
brain concentrations of MPP1 observed in certain mouse
strains. Therefore, in this study we examined the
effects of MPTP on striatal dopaminergic terminal
losses in a genetic model, the tottering mouse. Tottering
is an autosomal recessive mutation, with homozygous
animals (tg,tg) exhibiting ataxia, an intermittent move-
ment disorder resembling focal myoclonus, and sei-
zures with behavioral arrest similar to human absence
epilepsy. Histological studies show a hyperinnervation
by adrenergic neurons arising from the locus ceruleus.
Biochemically, the tottering mouse displays a spectrum
of altered concentrations of neurotransmitters, en-
zymes, and receptors (Kostopoulos, 1992), with the
most notable a significant increase of tissue norepineph-
rine concentrations in numerous brain regions (Levitt
and Noebels, 1981; Levitt et al., 1987). We recently
reported that the tottering mouse strain also can be
characterized by elevated in vivo binding of radioli-
gands to VMAT2 in many regions of the brain (Kilbourn
et al., 1995). Molecular biology studies have identified a
gene for an a1A voltage-sensitive calcium channel,
which is mutated in tottering mice, although the func-
tional link between the mutation and the observed
biochemical and cytological abnormalities of the mu-
tant has not been established (Fletcher et al., 1996).
The tottering mouse represents an animal model of
increased monoaminergic innervation, and potentially
increased concentrations of VMAT2. In this study, we
examined the effects of MPTP on losses of dopaminergic
nerve terminals in the striatum of wild-type and homo-
zygous tottering mice; to minimize potential strain
differences in peripheral metabolism and neurotoxin
distribution, all studies were done in wild-type and
tottering mice derived from the C57BL/6J strain. As an
indicator of terminal loss, we employed measures of the
in vivo specific binding of (1)-a-[3H]dihydrotetrabena-
zine ((1)-[3H]DTBZ), a specific and high affinity (Kd 5
1.5 nM) radioligand for VMAT2 (Frey et al., 1997;
Kilbourn and Sherman, 1997).
MATERIALS AND METHODS
Materials
All studies were done using (1)-a-[3H]dihydrotetra-
benazine ((1)-[3H]DTBZ: 81 Ci/mmol), prepared by
custom tritiation as previously described (Kilbourn et
al., 1997).
Animals
Wild-type (1/1) and homozygous tottering (tg/tg)
C57BL/6J mice were obtained from a breeding colony
maintained at Texas A&M University, College Station,
Texas. Animals were 26–28 weeks old at the time of the
study. All procedures were approved by the University
of Michigan University Committee on Use and Care of
Laboratory Animals.
In vivo radioligand distribution studies
In vivo studies of radioligand distributions were done
by a well-established protocol (Kilbourn and Sherman,
1997) which will be briefly described here. Animals
were anesthetized (diethyl ether), injected via the tail
vein with 5–10 µCi of (1)-[3H]DTBZ in saline solution,
and allowed to awaken. After 10 min, the animals were
anesthetized (ether) and killed by decapitation. The
brains were then rapidly removed and dissected into
regions of interest (striatum, whole cortex, hippocam-
pus, hypothalamic region, and cerebellum). Tissue
samples were weighed, digested, and counted for tri-
tium using liquid scintillation counting. Data was
calculated as the percent injected dose per gram of
tissue (%ID/g). Specific striatal binding of (1)-[3H]DTBZ
was calculated as the ratio [(%ID/gstriatum 2 %ID/
gcerebellum)/%ID/gcerebellum].
Statistics
Comparisons between groups were examined first by
ANOVA, with significant interactions further tested
using unpaired Student’s t-tests. A significance level of
0.05 was used throughout the study.
RESULTS
In control animals (no MPTP pretreatment), the in
vivo distribution of (1)-[3H]DTBZ in the brains of both
wild-type and tottering mice showed the expected rank
order of VMAT2 binding among brain regions (Vander
Borght et al., 1995), with higher concentrations in the
striatum and hypothalamic region, and essentially
equivalent and lower values in the cortex, hippocam-
pus, and cerebellum (Table I). This rank order was also
evident in the MPTP-treated animals, although the
differences between regions of high (striatum) and low
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(cerebellum) concentrations of transporters was dimin-
ished in most groups.
Treatment of wild-type and tottering C57BL/6 mice
with MPTP produced variable losses of specific striatal
binding of (1)-[3H]DTBZ (Fig. 1). A three-way ANOVA
analysis of the combined specific striatal binding data
showed significant (P , 0.01) effects of strain, sex, and
treatment. For the combined dataset, there was a
significant interaction between sex plus treatment (F 5
14.4, P 5 0.0006), but not between strain and treatment
(F 5 1.6, P 5 0.22), strain plus sex (F 5 3.3, P 5 0.078)
or an interaction of all three variables (F 5 0.73, P 5
0.4).
The effects of sex, strain, and MPTP treatment were
then further examined by comparisons between any
two groups of animals. In control groups of both wild-
type and tottering mice there were no significant gender
differences in specific striatal (1)-[3H]DTBZ binding.
For female mice, there were no differences between
wild-type and tottering mice; in males, however, there
was an apparently higher specific striatal (1)-[3H]DTBZ
binding in the tottering mice (P , 0.001).
Changes in (1)-[3H]DTBZ binding after MPTP treat-
ment were both sex- and strain-dependent. In the
wild-type mice, neurotoxin treatment reduced striatal
binding in both females (-57%, P , 0.001 vs. 1/1
controls) and males (-71%, P , 0.001 vs. 1/1 controls),
and these gender differences in striatal (1)-[3H]DTBZ
binding were significant (P , 0.001). In tottering mice,
MPTP also produced smaller but significant decreases
of (1)-[3H]DTBZ binding in the males (-45%, P , 0.001
vs. tg/tg controls) and females (-26%, P 5 0.02 vs. tg/tg
controls). Finally, the MPTP-induced decreases in spe-
cific striatal (1)-[3H]DTBZ binding in the tottering mice
were smaller than the changes observed in the wild-
type mice, and this was highly significant for males (P
, 0.001) but did not quite reach significance for females
(P 5 0.067).
DISCUSSION
The vesicular monoamine transporter type 2 (VMAT2)
is a specific marker of presynaptic monoaminergic
nerve terminals. We (Frey et al., 1997; Vander Borght
et al., 1995) and others (Henry and Sherman, 1989;
Staley et al., 1997; Takahashi et al., 1997; Wilson et al.,
1996) have utilized radioligand binding to this trans-
porter as a measure of monoaminergic terminal integ-
rity; in the striatum, due to the preponderance of
dopaminergic projections, the measures of radioligand
binding to VMAT2 reflect mainly the integrity of the
dopaminergic system. In this study, we used the bind-
ing of the radioligand (1)-a-[3H]DTBZ to this trans-
porter as a measure of losses of terminals in specific
brain regions of mice following a sequence of injections
of the neurotoxin MPTP. The hypothesis being tested
was that the excessive noradrenergic innervation of the
tottering mouse brain, which should provide an accom-
panying increase in tissue concentrations of VMAT2,
TABLE I. Regional distribution of (1)-[3H]DTBZ in the brains of
wild-type (1,1) and tottering (tg,tg) C57BL/6J mice, with and












5 5 4 5
% Injected dose/g tissue
Striatum 8.48 6 1.04 7.72 6 0.64 8.20 6 0.42 8.85 6 1.37
Cortex 3.41 6 0.28 2.81 6 0.26 2.81 6 0.32 3.42 6 0.64
Hypothalamus 4.86 6 0.48 4.35 6 0.34 5.11 6 0.40 5.18 6 0.75
Hippocampus 3.38 6 0.33 2.79 6 0.19 2.87 6 0.30 3.52 6 0.51











6 4 5 5
% Injected dose/g tissue
Striatum 3.91 6 0.30 6.81 6 0.41 5.24 6 0.54 8.83 6 1.37
Cortex 2.69 6 0.11 3.1 6 0.31 2.96 6 0.24 3.53 6 0.49
Hypothalamus 3.09 6 0.09 5.47 6 0.37 3.61 6 0.37 7.14 6 1.07
Hippocampus 2.55 6 0.13 3.48 6 0.27 2.84 6 0.25 4.02 6 0.60
Cerebellum 2.73 6 0.12 3.55 6 0.28 2.85 6 0.21 4.01 6 0.46
Fig. 1. Specific (1)-[3H]DTBZ binding in striatum of control (no
MPTP) and MPTP-trated mice. Specific binding was calculated as the
ratio of tissue concentrations ratio, [(%ID/gstriatum 2 %ID/gcerebellum)/%ID/
gcerebellum]. Data are shown as mean 6 s.d.
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would provide a protective effect against the neurotoxic-
ity of MPTP.
In wild-type C57BL/6J mice, MPTP treatment pro-
duced a significant loss of in vivo striatal binding sites
for (1)-[3H]DTBZ. This loss, ranging from 57% in
females to 71% in males, is in reasonable agreement
with losses of tissue dopamine (Ali et al., 1993; Dluzen
et al., 1996; Marien et al., 1993; Reinhard et al., 1988;
Ricuarte et al., 1987a,b) and neuronal membrane dopa-
mine transporters (Cline et al., 1992: Donnan et al.,
1987; Kilbourn et al., 1991) measured after similar or
identical MPTP treatment regimens. The greater neuro-
toxicity in male animals is consistent with the observa-
tion that female mice are less sensitive to the toxin
(Dluzen et al., 1996; Freyaldenhoven et al., 1996; Miller
et al., 1997), perhaps due to protective effects of estra-
diol.
In the tottering mice, the toxic effects of MPTP on
binding of (1)-[3H]DTBZ to VMAT2 were diminished,
producing smaller losses of radioligand binding and,
presumably, smaller losses of dopaminergic terminals.
This protective effect was clearly significant in the male
tg/tg mice, with an indication that the same was true
for the female mice (although the data did not reach
significance). The simplest explanation of our results is
that the increased noradrenergic innervation of the
tottering mouse brain results in increased numbers of
VMAT2, and, by inference, increased numbers of synap-
tic vesicles and/or increased capacity of MPP1 storage
in the brain results in decreased toxicity of peripherally
administered MPTP. This explanation fits the data
obtained with the female tottering mice, where we
consistently found increased concentrations of VMAT2
binding sites in many regions of the brains of both
young mature (6–8 weeks: Kilbourn et al., 1995) and
older (26–28 weeks, this study) tottering mice, as
compared to age-matched wild-type C57BL/6 mice. In
male mice, however, where the numbers of in vivo
VMAT2 binding sites were equivalent or even slightly
lower in most regions of the brains of tottering mice at
26–28 weeks of age (the higher specific binding ratio for
the striatum is due to a lower cerebellar concentration,
not increased striatal binding sites), the blunting of the
toxicity of MPTP is not as easily explained. Due to the
lack of available young male tottering mice, we were
unable to determine if such animals exhibit increased
(1)-[3H]DTBZ binding, as do females of that age. The
greater sensitivity of male mice (of either type) is likely
not simply due to pharmacokinetics of the toxin, as no
gender differences in striatal MPP1 levels have been
reported for single or repeated MPTP administrations
to CD-1 mice (Miller et al., 1997).
In this study, we utilized an estimate of the specific
binding of the radioligand (1)-[3H]DTBZ in the stria-
tum, calculated as a ratio of radiotracer concentrations
in striatum and cerebellum; the latter is a region with a
very low concentration of VMAT2 binding sites (Henry
and Sherman, 1989; Vander Borght et al., 1995). Al-
though calculations of ratios to areas which represent
predominantly nonspecific binding is a common method
for in vivo radiotracer studies, and we have shown that
such ratios for (1)-[3H]DTBZ reduce the variance in the
data and produce good estimates of specific binding of
this radioligand (Kilbourn and Sherman, 1997), it
should be considered that unexpected changes in the
region of the brain used as the denominator (in this
instance, the cerebellum) can enhance or obscure
changes in the specific binding of radioligand in the
striatum. We therefore examined whether the de-
creases in the specific binding (the STR-CBL/CBL)
ratio correlated with changes in striatal or cerebellar
radiotracer concentrations. That analysis showed that
the specific binding ratio correlated with the striatal
(r2 5 0.68) but not at all with the cerebellar concentra-
tions (r2 5 0.02) of radioactivity. Not surprisingly, then,
use of simple striatal concentrations of radioligand
binding as an alternate in vivo measure also indicates a
protective effect of the tottering mutation; the striatal
radioactivity concentrations represent total radioli-
gand binding, a combination of specific (85%) and
nonspecific (15%) binding of (1)-[3H]DTBZ (Kilbourn et
al., 1995). Although there is a potential for MPTP
toxicity to monoaminergic nerve terminals in other
regions of the mammalian brain, including the cerebel-
lum, these treatments of C57BL/6 mice did not produce
any clear changes in (1)-[3H]DTBZ binding in any
other regions which could be attributed to monoaminer-
gic nerve terminal toxicity, and the use of the ratio
method to estimate specific binding in the striatum
appears justified.
Although a simple inverse relationship between con-
centrations of VMAT2 and MPTP toxicity is enticing,
other possible explanations for the enhanced resistance
of tottering mice need to be seriously considered. It has
been reported that depletion of brain norepinephrine
(NE) results in an enhancement of MPTP neurotoxicity
in mice and primates (Bing et al., 1994; Marien et al.,
1993), and an enhancement of methamphetamine neu-
rotoxicity in mice and rats (Fornai et al., 1996). Prior
lesioning with the neurotoxin DSP-4, which caused
severe decreases (77–96%) in tissue norepinephrine
levels in cortex, cerebellum, and hippocampus (regions
innervated from the locus ceruleus), produced signifi-
cantly greater MPTP-induced losses of striatal dopa-
mine (,75% loss after DSP-4 1 MPTP as compared to
,50% after MPTP alone (Fornai et al., 1997)). A clear
explanation of the norepinephrine effect on MPTP
toxicity is lacking; the DSP-4 treatment has no effect on
the sparse concentration of NE terminals in the stria-
tum, nor does the treatment with DSP-4 affect the
pharmacokinetics of MPTP or MPP1 in the striatum
(Fornai et al., 1997). If, however, it is accepted that loss
of NE exacerbates MPTP toxicity, then higher regional
brain levels of norepinephrine found in the tottering
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mouse brain (ranging from 125–300% of controls; Levitt
and Noebels, 1981) might be responsible for reducing,
in a manner yet unknown, the toxicity of MPTP in this
mutant strain. The involvement, if any, of norepineph-
rine might be tested in future studies by treatment of
tottering mice with the norepinephrine-depleting neuro-
toxin DSP-4 prior to administration of MPTP.
There may also be an effect due to differential han-
dling of calcium ions in the tottering mice. As the
genetic defect of the tottering mouse has been localized
to a region encoding a calcium channel (Fletcher et al.,
1996), it could be speculated that in these animals the
genetic defect leads to a dysfunction of that calcium
channel and perhaps differential handling of calcium
by dopaminergic neurons that carry the a1A channel
subunit. Alterations of the neuronal calcium balance
has also been postulated as part of the toxic cascade of
MPP1 action (Kass et al., 1988), and pretreatment of
animals with calcium channel antagonists can dimin-
ish neurotoxic effects of MPTP (Gerlach et al., 1993;
Kupsch et al., 1995). In the tottering mouse, then, it
could be postulated that the neurological defect results
in a beneficial effect in maintaining intracellular cal-
cium balance. Finally, it must be recognized that the
protective effects of the tottering mutation may lie in
any one of a number of other biochemical abnormali-
ties, known or unknown for this neurological mutant.
Our results showing decreases in MPTP toxicity in
mice with monoaminergic hyperinnervation (and with
likely higher levels of VMAT2), together with the prior
pharmacological and transgenic mice studies showing
enhanced MPTP toxicity in animals with fewer avail-
able vesicular monoamine transporters, would support
the hypothesis that MPTP toxicity is influenced by the
storage capacity of the monoaminergic vesicles. If we
ignore for now the questions of the roles of norepineph-
rine and calcium channels in tottering mice, can differ-
ences in MPTP toxicity between strains, or between
species, be so easily explained as simply differences in
intracellular compartmentalization? We recently re-
ported studies designed to evaluate the role of vesicular
storage in the relative toxicity of MPTP toward differ-
ent strains of mice. The brains of C57BL/6 and CD-1
mouse strains did not show any significant differences
in the striatal concentrations of binding sites for radio-
ligands specific for VMAT2 (Kilbourn and Frey, 1996),
but studies have shown that the C57BL/6 strain is
markedly sensitive to MPTP but that the CD-1 strain is
much less affected (Freyaldenhoven et al., 1996; Gio-
vanni et al., 1991; Sonsalla and Heikkila, 1988). Thus,
the greater MPTP sensitivity of the C57BL/6 strain
cannot be explained simply on the basis of levels of
VMAT2, but may include an inability to handle the
higher tissue levels of MPP1 which, for as yet unex-
plained reasons, are found in the brains of the C57BL/6
strain of mouse (Giovanni et al., 1991). Similarly,
differences in vesicular transporter numbers or func-
tion have been suggested as the reason for MPTP
resistance of rats (Russo et al., 1994; Staal et al., 1997),
with both a higher Vmax for MPP1 transport and a
higher number of (1)-[3H]DTBZ binding sites reported
in one study (Staal et al., 1997). In contrast, identical
Km and Vmax values for synaptosomal uptake of MPP1
were found in a second study comparing rats and two
mouse strains (Sundstrom and Samuelsson, 1997), and
we have found essentially identical numbers of in vitro
striatal binding sites for (1)-[3H]DTBZ in Sprague-
Dawley rat (3.8 fmol/µg protein), C57BL/6 mouse (3.12
fmol/µg protein) and CD-1 mouse (3.22 fmol/µg) (Frey et
al., 1997; Kilbourn and Frey, 1996). Although MPTP is
not an effective systemic neurotoxin in rats, when
injected directly into the striatum at a sufficient concen-
tration MPP1 is clearly neurotoxic (Jenkins et al.,
1996), likely through binding to complex I sites (Kil-
bourn et al., 1997). Thus, it remains unclear if changes
in the numbers or functions of VMAT2 are the only
factors responsible for species or strain sensitivity to
MPTP. Neurological mutants such as the tottering offer
one more model for the study of factors crucial for
MPTP toxicity.
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